Transplantation outcomes
UPIN . | Days to ANC greater than 0.5 × 109/L . | Days to platelet count greater than 20 × 109/L . | Donor chimerism on transplantation, day +30/+100 . | Bcr-Abl/Abl ratio, day + 100 . | Toxicity (grade) . | Infections . | aGVHD (grade) . | cGVHD . | Best response . | Relapse . | DFS, mo . | Status at last follow-up . | Survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13 | 19 | 100% | NA | None | None | None | None | CMR | No | 13+ | CMR | 13+ |
| 2 | 14 | 54 | 100% | 0.0471 | NV (1) | Hemorrhagic cystitis | Skin (2) | Skin | CMR | No | 19+ | CMR | 19+ |
| 3 | 17 | 19 | 100% | 0.008 | D (1), NV (2), M (2) | None | None | None | CMR | No | 21+ | CMR | 21+ |
| 4 | 15 | 17 | 100% | 0 | None | C difficile, hemorrhagic cystitis | None | Skin | CMR | No | 24+ | CMR | 24+ |
| 5 | 13 | 43 | 100% | 0.01 | NV (2) | CMV | None | Skin | CMR | Yes | 6 | Dead | 7 |
| 6 | 12 | 14 | 100% | 0.046 | NV (1), D (1) | Bacterial pneumonia, CMV | Ocular (1) | Liver | MMR | Yes | 6 | Dead | 11 |
| 7 | 10 | 12 | 100% | 0 | None | CMV | Skin (2) | None | CMR | No | 17+ | CMR | 17+ |
| 8 | 12 | 27 | 100% | 0 | LFT (1), NV (2), D (2) | None | Skin (2) | None | CMR | No | 20+ | CMR | 20+ |
| 9 | 11 | 24 | 100% | 0 | None | None | GI (1) | None | MMR | No | 22+ | MMR | 22+ |
| 10 | 13 | NA | Mixed | NA | M (2), D (2) | Enterococcus pneumonia | Skin (2), Liver (1) | NA | PD | Yes | 0 | Dead | 4 |
UPIN . | Days to ANC greater than 0.5 × 109/L . | Days to platelet count greater than 20 × 109/L . | Donor chimerism on transplantation, day +30/+100 . | Bcr-Abl/Abl ratio, day + 100 . | Toxicity (grade) . | Infections . | aGVHD (grade) . | cGVHD . | Best response . | Relapse . | DFS, mo . | Status at last follow-up . | Survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13 | 19 | 100% | NA | None | None | None | None | CMR | No | 13+ | CMR | 13+ |
| 2 | 14 | 54 | 100% | 0.0471 | NV (1) | Hemorrhagic cystitis | Skin (2) | Skin | CMR | No | 19+ | CMR | 19+ |
| 3 | 17 | 19 | 100% | 0.008 | D (1), NV (2), M (2) | None | None | None | CMR | No | 21+ | CMR | 21+ |
| 4 | 15 | 17 | 100% | 0 | None | C difficile, hemorrhagic cystitis | None | Skin | CMR | No | 24+ | CMR | 24+ |
| 5 | 13 | 43 | 100% | 0.01 | NV (2) | CMV | None | Skin | CMR | Yes | 6 | Dead | 7 |
| 6 | 12 | 14 | 100% | 0.046 | NV (1), D (1) | Bacterial pneumonia, CMV | Ocular (1) | Liver | MMR | Yes | 6 | Dead | 11 |
| 7 | 10 | 12 | 100% | 0 | None | CMV | Skin (2) | None | CMR | No | 17+ | CMR | 17+ |
| 8 | 12 | 27 | 100% | 0 | LFT (1), NV (2), D (2) | None | Skin (2) | None | CMR | No | 20+ | CMR | 20+ |
| 9 | 11 | 24 | 100% | 0 | None | None | GI (1) | None | MMR | No | 22+ | MMR | 22+ |
| 10 | 13 | NA | Mixed | NA | M (2), D (2) | Enterococcus pneumonia | Skin (2), Liver (1) | NA | PD | Yes | 0 | Dead | 4 |
ANC indicates absolute neutrophil count; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; DFS, disease-free survival; NA, not applicable; CMR, complete molecular response; N, nausea; V, vomiting; D, diarrhea; M, mucositis; C difficile, Clostridium difficile; CMV, cytomegalovirus; MMR, major molecular response; LFT, increase of the liver functional tests; GI, gastrointestinal; and PD, progressive disease.